Clinical Evidence: What Studies Show About These Treatments
Weight Loss Results: Wegovy or Mounjaro or Ozempic Clinical Evidence
When comparing Wegovy, Mounjaro, or Ozempic, understanding the clinical evidence becomes crucial for making an informed decision. The STEP trial programme provides robust evidence for Wegovy's effectiveness as a prescription-only medicine for weight management. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% maintained over 2 years, highlighting the long-term potential of this treatment approach.
Mounjaro operates through a different mechanism as a dual GIP and GLP-1 receptor agonist, while it's important to note that Ozempic is licensed exclusively for type 2 diabetes management in the UK. The SURMOUNT trials investigating tirzepatide (Mounjaro's active ingredient) for weight management showed promising results, though direct comparison between different trial designs and patient populations isn't scientifically appropriate. Both Wegovy and Mounjaro are available from EverydayMeds following appropriate clinical assessment—your prescriber can help determine which treatment approach aligns with your individual health profile and weight management goals.
Pricing Structure for Wegovy or Mounjaro or Ozempic Access
EverydayMeds offers transparent pricing for prescription weight management treatments, with Wegovy single pens starting from £79.99 for the 0.25mg starter dose. The complete dose escalation includes 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the 2.4mg maintenance dose at £209.99. Our Getting Started bundles provide convenient multi-pen supply, such as the Intro Duo (0.25mg and 0.5mg) for £169.99, allowing patients to secure their initial treatment phases in one order. New customers apply discount code FIRST40 at checkout to reach these final prices, while returning customers use DOSE25.
Mounjaro pricing follows a different structure reflecting its unique dual-agonist formulation and dosing schedule. Bundle options focus on convenience rather than cost savings, ensuring patients maintain consistent supply throughout their treatment journey. The 3-minute online clinical assessment process remains the same regardless of which prescription-only medicine your prescriber recommends. Express prescriber review is available within 24 hours for an additional fee, with standard review completed within 3 working days through our GPhC-registered pharmacy services (#9012878).
STEP Trial Evidence for Wegovy or Mounjaro or Ozempic Comparison
The STEP clinical trial programme represents the gold standard evidence base for semaglutide's effectiveness in weight management. STEP 3 combined Wegovy with intensive behavioural therapy, achieving approximately 16% average weight loss, demonstrating how lifestyle interventions enhance pharmaceutical outcomes. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, highlighting potential benefits beyond weight management for appropriate patients.
When comparing published evidence, it's crucial to remember that different trials use varying endpoints, patient populations, and methodologies. Both Wegovy and Mounjaro have demonstrated efficacy in their respective clinical programmes, but head-to-head comparisons require careful interpretation by qualified healthcare professionals. Your prescriber will consider your individual medical history, contraindications, and treatment goals when recommending between available options.
How Wegovy Works Compared to Mounjaro or Ozempic Mechanisms
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones responsible for blood sugar regulation and appetite control. This medication works primarily in the brain's appetite centres, reducing food cravings and promoting feelings of fullness after smaller meals. The once-weekly injection using Novo Nordisk's FlexTouch pen device provides consistent medication levels throughout the week. Unlike Ozempic, which contains the same active ingredient but is licensed only for type 2 diabetes management, Wegovy is specifically formulated and approved for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. The medication must be used alongside a reduced-calorie diet and increased physical activity to achieve optimal results, as demonstrated in the clinical trial programmes.
Ordering Process for Wegovy or Mounjaro or Ozempic Through EverydayMeds
Accessing prescription weight management treatments through EverydayMeds begins with our 3-minute online clinical assessment, designed to capture essential medical information for prescriber review. Our qualified prescribers evaluate each assessment against NICE guidelines and MHRA licensing criteria, ensuring appropriate patient selection for either Wegovy or Mounjaro based on individual circumstances. Standard prescriber review is completed within 3 working days, though express 24-hour review is available for patients requiring faster access to treatment. Once approved, medications are dispatched via next-day delivery using specialist cold-chain transport to maintain the 2-8°C storage requirements. Our GPhC-registered pharmacy (#9012878) ensures all medications meet pharmaceutical quality standards, with full traceability from manufacturer to patient delivery.
Storage and Practical Considerations for Wegovy or Mounjaro or Ozempic
Wegovy offers practical storage advantages, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature tolerance. This makes Wegovy particularly suitable for patients who travel frequently or have limited refrigeration access. The FlexTouch pen device is pre-filled and ready to use, requiring no mixing or preparation before injection. Dose escalation follows a mandatory schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg for maintenance from week 17 onwards. Patients cannot skip dose escalation steps, as this increases the risk of gastrointestinal side effects that may impact treatment continuation and long-term success.
UK-Specific Weight Loss Results Data for Wegovy or Mounjaro or Ozempic
Real-world evidence from UK clinical practice supports the findings observed in international clinical trials, with patients achieving meaningful weight loss when treatments are prescribed alongside comprehensive lifestyle interventions. NHS England's adoption of NICE guidance TA875 for Wegovy reflects confidence in the clinical evidence base and cost-effectiveness analysis specific to UK healthcare delivery. The requirement for specialist weight management service referral in NHS settings ensures patients receive appropriate ongoing support throughout their treatment journey.
Private healthcare access through registered pharmacies like EverydayMeds allows patients to begin treatment while NHS waiting times remain substantial in many regions. Both Wegovy and Mounjaro are subject to MHRA additional monitoring, indicated by the Black Triangle (▼) symbol, reflecting their relatively recent approval and ongoing safety data collection. This enhanced monitoring demonstrates regulatory commitment to patient safety while allowing access to innovative treatments for appropriate candidates.
Making Your Treatment Choice: Wegovy or Mounjaro or Ozempic Guidance
Your prescriber will consider multiple factors when recommending between available treatments, including your medical history, current medications, lifestyle factors, and treatment preferences. The decision between Wegovy's established GLP-1 mechanism and Mounjaro's innovative dual-agonist approach requires individual assessment of potential benefits and risks. Remember that Ozempic, while containing the same active ingredient as Wegovy, is licensed exclusively for type 2 diabetes management and cannot be legally prescribed for weight management purposes in the UK. Both Wegovy and Mounjaro are available from EverydayMeds following appropriate clinical assessment—our experienced prescribers can help determine which treatment approach offers the best potential outcomes for your individual circumstances. Access begins with our simple online assessment, with new customers using discount code FIRST40 and returning customers applying DOSE25 at checkout to reach our competitive pricing structure.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
